Switch theme
Sign up to access all valuation multiples
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.
1944
3.4K+
LTM Revenue $1.1B
Last FY EBITDA $241M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hisamitsu Pharmaceutical has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Hisamitsu Pharmaceutical achieved revenue of $1.1B and an EBITDA of $241M.
Hisamitsu Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hisamitsu Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $635M | XXX | $626M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $241M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 22% | XXX | XXX | XXX |
| EBIT | $133M | XXX | $130M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $152M | XXX | $149M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hisamitsu Pharmaceutical's stock price is JPY 4109 (or $28).
Hisamitsu Pharmaceutical has current market cap of JPY 300B (or $2.1B), and EV of JPY 175B (or $1.2B).
See Hisamitsu Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $2.1B | XXX | XXX | XXX | XXX | $2.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hisamitsu Pharmaceutical has market cap of $2.1B and EV of $1.2B.
Hisamitsu Pharmaceutical's trades at 1.1x EV/Revenue multiple, and 5.2x EV/EBITDA.
Equity research analysts estimate Hisamitsu Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hisamitsu Pharmaceutical has a P/E ratio of 13.6x.
See valuation multiples for Hisamitsu Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBIT | 9.0x | XXX | 9.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.6x | XXX | 14.7x | XXX | XXX | XXX |
| EV/FCF | 5.5x | XXX | 34.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHisamitsu Pharmaceutical's last 12 month revenue growth is 6%
Hisamitsu Pharmaceutical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Hisamitsu Pharmaceutical's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hisamitsu Pharmaceutical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hisamitsu Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 27% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hisamitsu Pharmaceutical acquired XXX companies to date.
Last acquisition by Hisamitsu Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Hisamitsu Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hisamitsu Pharmaceutical founded? | Hisamitsu Pharmaceutical was founded in 1944. |
| Where is Hisamitsu Pharmaceutical headquartered? | Hisamitsu Pharmaceutical is headquartered in Japan. |
| How many employees does Hisamitsu Pharmaceutical have? | As of today, Hisamitsu Pharmaceutical has 3.4K+ employees. |
| Who is the CEO of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical's CEO is Mr. Kazuhide Nakatomi. |
| Is Hisamitsu Pharmaceutical publicy listed? | Yes, Hisamitsu Pharmaceutical is a public company listed on TKS. |
| What is the stock symbol of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical trades under 4530 ticker. |
| When did Hisamitsu Pharmaceutical go public? | Hisamitsu Pharmaceutical went public in 1962. |
| Who are competitors of Hisamitsu Pharmaceutical? | Similar companies to Hisamitsu Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical's current market cap is $2.1B |
| What is the current revenue of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Hisamitsu Pharmaceutical? | Current revenue multiple of Hisamitsu Pharmaceutical is 1.1x. |
| Is Hisamitsu Pharmaceutical profitable? | Yes, Hisamitsu Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current FCF of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical's last 12 months FCF is $219M. |
| What is Hisamitsu Pharmaceutical's FCF margin? | Hisamitsu Pharmaceutical's last 12 months FCF margin is 20%. |
| What is the current EV/FCF multiple of Hisamitsu Pharmaceutical? | Current FCF multiple of Hisamitsu Pharmaceutical is 5.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
